These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7894259)

  • 21. Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic treatment.
    Sharma RP; Bissette G; Janicak P; Davis JM; Nemeroff CB
    Schizophr Res; 1994 Sep; 13(2):173-7. PubMed ID: 7986775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced CSF neurotensin concentration in drug-free schizophrenic patients.
    Lindström LH; Widerlöv E; Bisette G; Nemeroff C
    Schizophr Res; 1988; 1(1):55-9. PubMed ID: 3154507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia.
    Sasayama D; Hattori K; Teraishi T; Hori H; Ota M; Yoshida S; Arima K; Higuchi T; Amano N; Kunugi H
    Schizophr Res; 2012 Aug; 139(1-3):201-6. PubMed ID: 22742979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inositol phospholipid turnover in platelets of schizophrenic patients.
    Das I; Essali MA; de Belleroche J; Hirsch SR
    Prostaglandins Leukot Essent Fatty Acids; 1992 May; 46(1):65-6. PubMed ID: 1352897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment.
    Essali MA; Das I; de Belleroche J; Hirsch SR
    Biol Psychiatry; 1990 Sep; 28(6):475-87. PubMed ID: 1977477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites.
    Lindström LH; Besev G; Gunne LM; Terenius L
    Psychiatry Res; 1986 Oct; 19(2):93-100. PubMed ID: 2431427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.
    Plitman E; Chavez S; Nakajima S; Iwata Y; Chung JK; Caravaggio F; Kim J; Alshehri Y; Chakravarty MM; De Luca V; Remington G; Gerretsen P; Graff-Guerrero A
    Psychiatry Res Neuroimaging; 2018 Mar; 273():16-24. PubMed ID: 29414127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
    Kofman O; Belmaker RH
    Biol Psychiatry; 1993 Dec; 34(12):839-52. PubMed ID: 8110911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.
    Glovinsky D; Kalogeras KT; Kirch DG; Suddath R; Wyatt RJ
    Schizophr Res; 1994 Feb; 11(3):273-6. PubMed ID: 7910756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia.
    Wahlbeck K; Ahokas A; Miettinen K; Nikkilä H; Rimón R
    Schizophr Bull; 1998; 24(3):391-7. PubMed ID: 9718631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms.
    Prell GD; Green JP; Kaufmann CA; Khandelwal JK; Morrishow AM; Kirch DG; Linnoila M; Wyatt RJ
    Schizophr Res; 1995 Jan; 14(2):93-104. PubMed ID: 7711000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia.
    Wahlbeck K; Ahokas A; Nikkilä H; Miettinen K; Rimón R
    Schizophr Res; 2000 Jan; 41(2):335-40. PubMed ID: 10708342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
    Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
    Beinfeld MC; Garver DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):601-9. PubMed ID: 1956989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of effect of 6 g inositol treatment of post-ECT cognitive function in humans.
    Levine J; Pomerantz T; Stier S; Belmaker RH
    J Psychiatr Res; 1995; 29(6):487-9. PubMed ID: 8642546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures.
    Peters J; Van Kammen DP; Gelernter J; Yao J; Shaw D
    Schizophr Res; 1990; 3(5-6):287-94. PubMed ID: 2178001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.
    Maas JW; Bowden CL; Miller AL; Javors MA; Funderburg LG; Berman N; Weintraub ST
    Schizophr Bull; 1997; 23(1):147-54. PubMed ID: 9050120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid tau protein levels in schizophrenia.
    Schönknecht P; Hempel A; Hunt A; Seidl U; Volkmann M; Pantel J; Schröder J
    Eur Arch Psychiatry Clin Neurosci; 2003 Apr; 253(2):100-2. PubMed ID: 12799749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
    Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP
    Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.